Show simple item record

dc.contributor.authorTerpos, E
dc.contributor.authorMorgan, G
dc.contributor.authorDimopoulos, MA
dc.contributor.authorDrake, MT
dc.contributor.authorLentzsch, S
dc.contributor.authorRaje, N
dc.contributor.authorSezer, O
dc.contributor.authorGarcía-Sanz, R
dc.contributor.authorShimizu, K
dc.contributor.authorTuresson, I
dc.contributor.authorReiman, T
dc.contributor.authorJurczyszyn, A
dc.contributor.authorMerlini, G
dc.contributor.authorSpencer, A
dc.contributor.authorLeleu, X
dc.contributor.authorCavo, M
dc.contributor.authorMunshi, N
dc.contributor.authorRajkumar, SV
dc.contributor.authorDurie, BGM
dc.contributor.authorRoodman, GD
dc.date.accessioned2018-07-10T13:15:10Z
dc.date.issued2013-06
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, 31 (18), pp. 2347 - 2357
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2017
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2012.47.7901
dc.description.abstractPurpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.Methodology An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members.Recommendations Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
dc.formatPrint-Electronic
dc.format.extent2347 - 2357
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectBone Diseases
dc.subjectOsteonecrosis
dc.subjectDiphosphonates
dc.subjectClodronic Acid
dc.subjectImidazoles
dc.subjectPositron-Emission Tomography
dc.subjectTomography, X-Ray Computed
dc.subjectMagnetic Resonance Imaging
dc.subjectCombined Modality Therapy
dc.subjectDrug Therapy, Combination
dc.subjectRadiotherapy
dc.subjectMedical Oncology
dc.subjectInternational Cooperation
dc.subjectBone Density Conservation Agents
dc.subjectFractures, Bone
dc.subjectPractice Guidelines as Topic
dc.subjectAdministration, Intravenous
dc.subjectZoledronic Acid
dc.subjectPamidronate
dc.subjectOutcome Assessment, Health Care
dc.titleInternational Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/jco.2012.47.7901
rioxxterms.licenseref.startdate2013-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue18
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.publication-statusPublished
pubs.volume31
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMorgan, Gareth Johnen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record